WebApr 3, 2024 · On July 23, 2024, phase B of the trial was interrupted as a result of the first interim analysis on the basis of the Bayesian adaptive design. Results: Of the 517 patients enrolled in phase A, 154 (30%) had ventricular tachycardia, 56 (11%) received an appropriate shock over a median follow-up of 2.4 years (interquartile range, 1.4–4.4), and ... WebMar 4, 2024 · Description: The goal of the trial was to evaluate computed tomography (CT) compared with invasive coronary angiography among patients with stable chest pain and intermediate pretest probability of obstructive coronary artery disease. Study Design Randomization Parallel
EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the ... - PubMed
WebEMBARK is a phase 3 clinical trial which will enroll 1860 patients. The trial began in 2014 and the primary completion date is 2024. Possible patient benefits include increasing the … WebJan 14, 2024 · Below are current clinical trials. 124 studies in Cardiovascular Medicine (open studies only). Filter this list of studies by location, status and more. A Study to … rainbow plant life vegan chili
Ten-Year Follow-Up Survival of the Medicine, Angioplasty, or …
WebSep 19, 2024 · 7 Facts from our Embark Review. The world’s first company to offer a “canine relative finder,” meaning you can find and connect with your dog’s siblings, … WebAug 12, 2024 · Methods and analysis: EMBARK is a randomised, phase 3 study of high-risk patients with nmCSPC, a PSADT of ≤9 months and a screening PSA of ≥2 ng/mL above … WebOct 30, 2024 · What we have learnt: The EMPEROR-Preserved trial is the first randomized controlled trial testing the efficacy and safety of SGLT2 inhibitor (empagliflozin) in patients with HFpEF. The trial proves that SGLT2 inhibitors (empagliflozin) can significantly reduce HF hospitalization with neutral effect on cardiovascular (CV) death. rainbow plasterceil sdn bhd